Patients with myelodysplastic syndromes often show anemia, leukopenia and thrombocytopenia on routine blood tests.
Patients with myelodysplastic syndromes are often associated with pathological hematopoiesis of the bone marrow, and suppression of the normal hematopoiesis of the bone marrow, i.e., failure of the erythroid, granulomatous, or megakaryotic lineages to produce blood, results in anemia and a decrease in white blood cell and/or platelet counts. The anemia may be monohematopoietic, or any two hemopoietic lineages, and in most patients, all three lineages are reduced at the same time.
Myelodysplastic syndromes can occur at any age, but are more common in older patients; myelodysplastic syndromes are diagnosed by bone marrow aspiration and biopsy, fluorescence immunohybridization (FISH), and other tests.
When patients develop refractory anemia and unexplained hematopoiesis, they need to go to the hematology department in time to improve bone marrow aspiration and biopsy, fluorescence immunohybridization technology (FISH) and other tests to make a clear diagnosis, and develop individualized treatment plans according to the patient’s specific condition.